MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)

被引：0
|
作者：
Kull, M. [1 ]
Grosicki, S. [2 ]
Yeh, S. -P. [3 ]
Huang, J. S. Y. [4 ]
Byun, J. M. [5 ]
DiRienzo, C. [6 ]
Viqueira, A. [7 ]
机构：
[1] Univ Hosp Ulm, Dept Hematol, Ulm, Germany
[2] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland
[3] China Med Univ Hosp, Taichung, Taiwan
[4] Taiwan Univ Hosp, Taipei, Taiwan
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Pfizer Inc, New York, NY USA
[7] Pfizer SLU, Madrid, Spain
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1105
引用
收藏
页码：314 / 314
页数：1
相关论文
共 50 条
  • [1] MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
    Grosicki, Sebastian
    Yeh, Su-Peng
    Huang, Jeffrey S. Y.
    Byun, Ja Min
    DiRienzo, Christine
    Viqueira, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Phase 3 randomized study of Daratumumab plus lenalidomide and Dexamethasone (D-Rd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)
    Weisel, K.
    Facon, T.
    Kumar, S.
    Plesner, T.
    Orlowski, R. Z.
    Moreau, P.
    Bahlis, N.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Mace, J. R.
    Ahmadi, T.
    Chiu, C.
    Wang, J.
    van Rampelbergh, R.
    Uhlar, C. M.
    Kobos, R.
    Qi, M.
    Usmani, S. Z.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 194 - 194
  • [3] Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
    Facon, Thierry
    Kumar, Shaji K.
    Plesner, Torben
    Orlowski, Robert Z.
    Moreau, Philippe
    Bahlis, Nizar
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Mace, Joseph R.
    Ahmadi, Tahamtan
    Chiu, Christopher
    Wang, Jianping
    Van Rampelbergh, Rian
    Uhlar, Clarissa M.
    Kobos, Rachel
    Qi, Ming
    Usmani, Saad Z.
    BLOOD, 2018, 132
  • [4] MajesTEC-7: A Phase 3, Randomized Study of Teclistamab plus Daratumumab plus Lenalidomide (Tec-DR) Versus Daratumumab plus Lenalidomide plus Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant
    Krishnan, Amrita Y.
    Manier, Salomon
    Terpos, Evangelos
    Usmani, Saad
    Khan, Josephine
    Pearson, Rachel
    Girgis, Suzette
    Guo, Yue
    McAleer, Dana
    Olyslager, Yunsi
    Kampfenkel, Tobias
    van de Donk, Niels W. C. J.
    BLOOD, 2022, 140 : 10148 - 10149
  • [5] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia
    Bahlis, Nizar
    Facon, Thierry
    Usmani, Saad Z.
    Kumar, Shaji K.
    Plesner, Torben
    Orlowski, Robert Z.
    Touzeau, Cyrille
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael E.
    Venner, Christopher P.
    Weisel, Katja C.
    Krevvata, Maria
    Pei, Huiling
    Wang, Jianping
    Van Rampelbergh, Rian
    Ukropec, Jon
    Uhlar, Clarissa M.
    Kobos, Rachel
    Perrot, Aurore
    BLOOD, 2019, 134
  • [6] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [7] Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study
    Kumar, Shaji K.
    Facon, Thierry
    Usmani, Saad Z.
    Plesner, Torben
    Orlowski, Robert Z.
    Touzeau, Cyrille
    Basu, Supratik
    Bahlis, Nizar J.
    Goldschmidt, Hartmut
    O'Dwyer, Michael E.
    Venner, Christopher P.
    Weisel, Katja
    Hulin, Cyrille
    Karlin, Lionel
    Preis, Meir
    Broyl, Annemiek
    Renwick, William
    Hansson, Markus
    Krevvata, Maria
    Wang, Jianping
    Van Rampelbergh, Rian
    Ukropec, Jon
    Uhlar, Clarissa M.
    Kobos, Rachel
    Perrot, Aurore
    BLOOD, 2020, 136
  • [8] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study
    Kumar, S. K.
    Moreau, P.
    Bahlis, N.
    Facon, T.
    Plesner, T.
    Orlowski, R. Z.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Weisel, K.
    Raje, N.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Wang, G.
    Krevvata, M.
    Carson, R.
    Borgsten, F.
    Usmani, S. Z.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 183 - 184
  • [9] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
    Kumar, Shaji K.
    Moreau, Philippe
    Bahlis, Nizar Jacques
    Facon, Thierry
    Plesner, Torben
    Orlowski, Robert Z.
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Raje, Noopur
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Pei, Huiling
    Krevvata, Maria
    Carson, Robin
    Borgsten, Fredrik
    Usmani, Saad
    BLOOD, 2022, 140 : 10150 - 10153
  • [10] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
    Facon, Thierry
    Cook, Gordon
    Usmani, Saad Z.
    Hulin, Cyrille
    Kumar, Shaji
    Plesner, Torben
    Touzeau, Cyrille
    Bahlis, Nizar J.
    Basu, Supratik
    Nahi, Hareth
    Goldschmidt, Hartmut
    Quach, Hang
    Mohty, Mohamad
    Venner, Christopher P.
    Weisel, Katja
    Raje, Noopur
    Hebraud, Benjamin
    Belhadj-Merzoug, Karim
    Benboubker, Lotfi
    Decaux, Olivier
    Manier, Salomon
    Caillot, Denis
    Ukropec, Jon
    Pei, Huiling
    Van Rampelbergh, Rian
    Uhlar, Clarissa M.
    Kobos, Rachel
    Zweegman, Sonja
    LEUKEMIA, 2022, 36 (04) : 1066 - 1077
12345